• 한국식품위생안전성학회지
• /
• 제25권2호
• /
• pp.162-169
• /
• 2010

식품위생법개정에 의한 음식점 식육 원산지 표시제가 시행됨에 따라 표시제도의 정착을 위해 마련한 과학적 한우판별 시험법을 이용하여 소고기 원산지 표시제에 대한 실패를 전국적 규모로 점검하였다. 본 연구에 사용한 한우판별시험법은 앞선 사업에서 검증된 90개의 한우판별용 SNP 바이오마커를 이용한 시험방법으로 소고기원산지표시제의 제도정착에 큰 기여를 하고 있다. 2009년도 식품안전관리지침에 계획도니 음식점 소고기 원산지 표시제 시행 대상 음식점으로는 구이용 쇠고기 판매 음식점으로서 영업장 면접이 $100m^2$이상인 곳 가운데 서울지역 48개 시료 및 지방 168개 시료 등 총 216건에 대하여 원산지 표시실태 모니터링 검사를 실시하였으며, 그 결과 총 검체의 1.3% (3건/216건)가 허위표시임이 파악되었다. 이는 2008년도의 모니터링 검사를 통하여 확인한 허위표시 비율인 5.14%에 비해 감소한 결과로 "음식점식육원산지표시제"가 점차 정착되고 있는 것으로 판단된다. 또한, 한우판별시험법이 마련되기 전 실시했던 음식점 소고기 원산지 표시에 대한 모니터링 실시결과 2005년 34.0%, 2006년 30.1%으로 나타난 반면 한우판별시험법이 확립된 후 모니터링 결과는 2007년도 3.2%, 2008년도 5.14%으로 나타나 한우판별시헙법의 확립이 음식점 소고기 원산지 표시제에 큰 기여를 하고 있음을 증명해 주고 있다.

• Journal of Pharmaceutical Investigation
• /
• 제34권1호
• /
• pp.57-71
• /
• 2004

The objective of this study was to provide a better understanding of SUPAC-IR and its application in handling postapproval changes to immediate release solid oral dosage forms. Originally, SUPAC-IR was aimed at reducing the regulator burdern of the industry when they were making postapproval changes, but still at maintaining the formulation quality and performance of a drug product. The postapproval changes that were covered under SUPAC-IR included variations in the components ad composition of formulation, the site of manufacturing, batch size, manufacturing equipment, and manufacturing process. The guidance defined levels of changes, based on the likelihood of risk ocurrence and potential impact of postapproval changes upon the safety and efficacy of a drug product I suggested what a type of fing report should be submitted to the FDA for each level of change. Chemist, manufacturing, and control tests to be executed were also recommended for each change level The important tests specified in the guidance included batch release, stability, in vitro dissolution, and in vivo bioequivalence tests. However, there have been strong demands on revising the current SUPAC-IR in order to resolve some issues and to improve its usefulness in evaluating postapproval changes to immediate release solid oral dosage forms. In particular, the rigorous requirement of case C dissolution test and the definition of batch size were challenged by both academia and the industry. A revision work was in progress to reflect these inputs and to expand the utility of SUPAC-IR. As a result of these concerted efforts, an updated 2nd version of SPAC-IR would be likely to be issued ver soon to the public.

• Journal of Pharmaceutical Investigation
• /
• 제34권3호
• /
• pp.229-254
• /
• 2004

The objective of this study was to scrutinize the rationale of SUPAC-MR and its application in processing postapproval changes to modified release solid oral dosage forms. The types of postapproval changes that were primarily covered with SUPAC-MR included variations in the components and composition, the site of manufacturing, batch size, manufacturing equipment, and manufacturing process. SUPAC-MR defined levels of postapproval changes that the industry might make. Classification of such categories was based on the likelihood of risk occurrence and potential impact of changes upon the safety and efficacy of approved drug products. In most cases, the changes could be classified into 3 levels. It described what chemistry, manufacturing, and control tests should be conducted for each change level. The important tests specified in SUPAC-MR were batch release, stability, in vitro dissolution, and in vivo bioequivalence tests. It then suggested what type of a filing report should be submitted to the FDA for each change level. In general, level 1 changes could be reported in an annual report, whereas level 2 and/or 3 changes could be submitted in changes-being-effected or prior approval supplements. It could be understood that the purpose of SUPAC-MR was to maintain the safety and quality of approved modified release solid oral dosage forms undergoing certain changes. At the same time, it contributed to providing a less burdensome regulatory process with the manufacturers when they wanted to make postapproval changes. European regulatory agencies also implemented SUPAC-like regulations in handling such changes to drug products. Therefore, in this study a recommendation was made for KFDA and the Korean industry to evaluate thoroughly the usefulness of these guidances and regulations in dealing with postapproval changes to modified release solid oral dosage forms.

• 대한임상검사과학회지
• /
• 제50권1호
• /
• pp.20-28
• /
• 2018

결핵(TB)은 Mycobacterium tuberculosis (MTB) 복합체의 구성원에 의한 세균 감염 질병이다. 결핵은 전 세계 인구의 1/3이 감염된 것으로 알려져 있으며, 한국에서는 매년 약 4만 명의 새로운 결핵환자가 발생한다. 또한, 비결핵 항상균 감염이 증가하고 있는 추세이다. 전통적인 결핵 및 비결핵 항상균 진단방법은 세균 배양으로 3~4주 이상이 소요된다. 따라서, 신속하고 정확한 결핵균(TB) 및 비결핵 항상균(NTM) 진단법의 필요성이 요구되고 있다. 결핵균 및 비결핵 항상균을 구분하기 위하여, 전 세계적으로 다양한 진단 방법이 개발되고 있다. 특히, 결핵균과 비결핵 항상균을 신속하고 정확한 동정의 요구가 증가함에 따라, 정확하고 신속하게 진단하기 위한 체외 진단 방법이 개발 되고 있다. 그러나 현재 결핵과 비결핵 항상균에 대한 체외 진단 시약의 성능 평가는 부족한 실정이다. 최근 식약청은 결핵균 및 비결핵 항상균 체외 진단 시약에 대한 가이드 라인을 발표했다. 본 연구에서는, 미국 FDA에 승인을 받은 결핵균 및 비결핵 항산균에 대한 체외 진단 시약의 성능을 검토하였다. 이 검토는 결핵균 및 비결핵 항상균 체외 진단 시약 평가에 유용한 참고 자료가 될것으로 사료된다.

• 식품과학과 산업
• /
• 제53권3호
• /
• pp.264-276
• /
• 2020

Ionizing radiation is one of the efficient non-thermal pasteurization methods. The US Food and Drug Administration (FDA) allows the use of ionizing radiation to a dose up to 10 kGy for controlling foodborne pathogens and extending the self-life of foods. Recently X-rays, generated on absorption of high energy electrons in an appropriate metal target, have been used commercially for sterilization purposes. X-rays have the advantages of higher penetration power than E-beams and absence of harmful radioactive sources, such as Cobalt-60 or Cesium-137 associated with gamma-rays. That is why it has continued to receive attention as an attractive alternative to gamma-ray or E-beam irradiation. In this article, the potential of X-ray irradiation for controlling foodborne pathogens in various food products and necessary pre-requisite knowledge for the introduction of X-ray irradiation to the Korean food industry will be provided.

• Toxicological Research
• /
• 제16권3호
• /
• pp.229-238
• /
• 2000

The purpose of reproductive toxicity studies is to evaluate all effects resulting from paternal or maternal exposure that interfere with conception, development, birth, and maturation of offspring. In 1966, the US Food and Drug Administration (US FDA) published guidelines for a three-segment study for drug testing to examine adverse effects on fertility and pregnancy. Three segments were proposed: Segment I, Study of Fertility and General Reproductive Performance, to provide information on breeding, fertility, nidation, parturition, neonatal effects and lactation: Segment II, Teratological study, to provide information on embryo toxicity and teratogenicity: and Segment III. perinatal and Postnatal Study, to provide information on late fetal development, labour and delivery, neonatal viability, and growth and lactation. The classic guideline is still used to this day with only monor modification throughout the world. In the present review, the principles and methods of reproductive toxicity studies are discussed with special attention given to scientific issues.

• 대한임상독성학회지
• /
• 제1권1호
• /
• pp.43-46
• /
• 2003

Phenypropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations. The side effects are hypertension, dysrhythmias, stroke, etc. The Food and Drug Administration (FDA) is taking steps to remove PPA from all drug products and has requested that all drug companies discontinue marketing products containg PPA due to high risk of hemorrhage stroke. But, in Korea now, patinets take products containg PPA with over the counter. We report here the case of PPA induced myocardial injury in a young woman who takes overdose for suicide.

• 약학회지
• /
• 제51권3호
• /
• pp.174-178
• /
• 2007

A reverse-phase high performance liquid chromatography method with electrospray ionization and detection by mass spectrometry is described for the simultaneous determination of doxifluridine and its active metabolite 5-flu-orouracil (5-FU) in monkey serum. The method has greater sensitivity and simpler process than previous published methods with good accuracy and precision. A proper liquid/liquid extraction was used to extract simultaneously doxifluridine and 5-FU which has considerable difference in the polarity. Extracts were analyzed using LC/MS/MS providing a short analysis time within 5 min. The lower limit of quantification was validated at 10.0 ng/ml of serum for both doxifluridine and 5-FU. Accuracy and precision of quality control (QC) samples for both analytes met FDA Guidance criteria of ±15% for average QC accuracy with coefficients of variation less than 15%. The method will be applicable for preclinical studies and bioequivalence studies.

• 대한의용생체공학회:의공학회지
• /
• 제41권1호
• /
• pp.62-66
• /
• 2020

Controlled drug release is important for effective treatment of cancer. Poly(DL-lactide-co-glycolide) acid (PLGA) is a Food and Drug Administration (FDA) approved polymer and have been extensively studied as drug delivery carriers with biodegradable and biocompatible properties. However, PLGA drug delivery carriers are limited due to the initial burst release of drug. Certain drugs require an early rapid release, but in many cases the initial rapid release can be inefficient, reducing therapeutic effects and also increasing side effects. Therefore, sustained release is important for effective treatment. Poly Lactic Acid stereo complex (PLA SC) is resistant to hydrolysis and has high stability in aqueous solutions. Therefore, in this work, PLGA based discoidal polymeric particles are modified by Poly Lactic Acid stereocomplex (PLAsc DPPs). PLAsc DPPs are 3 ㎛ in diameter, also showing a relatively sustained release profile. Fluorescein 5(6)-isothiocyanate (FITC) released from PLAsc DPPs was continuously observed until 38 days, which showed the initial release of FITC from PLAsc DPPs was about 3.9-fold reduced as compared to PLGA based DPPs at 1 hour.

• 무역학회지
• /
• 제48권3호
• /
• pp.131-150
• /
• 2023

본 연구는 한국 바이오헬스 산업에 대한 미국의 수입거부(Import Refusals) 대응 방안 모색을 목적으로 한다. 이를 위해 수입거부 품목과 유형에 대한 정보가 포함된 한국무역협회 통관거부사례 데이터베이스를 활용하여 팬데믹 시기의 동향 분석을 시행하였으며, FDA 위반코드(Violation Code)에 따라 거부사유까지 분석하였다. 추가적으로 단위거부율(URR)의 측정을 통해 수입거부 대응 수준도 파악하였다. 분석 결과, 한국 바이오헬스 산업에 대한 미국의 주요 수입거부 품목은 과거 콘택트렌즈에서 코로나-19 이후 진단키트와 의약품으로 확대된 것으로 나타났으며, 주요 수입거부 사유는 의료기기와 의약품 관련법의 규정 미준수와 제품 및 시설에 대한 FDA의 미승인으로 확인되었다. 한편 바이오헬스 주요 품목의 단위거부율은 산업 평균보다 높게 측정되어 미국 수입거부 대응 수준이 낮은 것으로 파악되었다. 또한 FDA 위반코드에 따라 품목별 수입거부 사유를 분석한 결과는 다음과 같다. 우선, 콘택트렌즈와 코로나바이러스 진단키트의 주요 위반사항은 부정표시(Misbranding)에 해당한다. 이는 FDA에 관련 통지나 정보가 규정대로 제공되지 않았거나, 시판 중인 기승인 의료기기(Predicate Device)와 비교하여 본질적 동등성을 입증하지 못한 경우가 많다. 반면, 의약품은 유효성 및 안전성 입증 관련 규정에 따라 신청서의 승인을 받지 못한 미승인 신약(Unapproved New Drug)에 해당한다. 결과적으로 바이오헬스 산업의 수입거부는 무역기술장벽(TBT)과 밀접한 관련이 있다.